Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
The recent covid crisis has provided important lessons for academia and industry regarding digital reorganization. Among the fascinating lessons from these times is the huge potential of data analytics and artificial intelligence. The crisis exponentially accelerated the adoption of analytics and ar...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/6/3261 |
| _version_ | 1797470841227706368 |
|---|---|
| author | Giuseppe Floresta Chiara Zagni Davide Gentile Vincenzo Patamia Antonio Rescifina |
| author_facet | Giuseppe Floresta Chiara Zagni Davide Gentile Vincenzo Patamia Antonio Rescifina |
| author_sort | Giuseppe Floresta |
| collection | DOAJ |
| description | The recent covid crisis has provided important lessons for academia and industry regarding digital reorganization. Among the fascinating lessons from these times is the huge potential of data analytics and artificial intelligence. The crisis exponentially accelerated the adoption of analytics and artificial intelligence, and this momentum is predicted to continue into the 2020s and beyond. Drug development is a costly and time-consuming business, and only a minority of approved drugs generate returns exceeding the research and development costs. As a result, there is a huge drive to make drug discovery cheaper and faster. With modern algorithms and hardware, it is not too surprising that the new technologies of artificial intelligence and other computational simulation tools can help drug developers. In only two years of covid research, many novel molecules have been designed/identified using artificial intelligence methods with astonishing results in terms of time and effectiveness. This paper reviews the most significant research on artificial intelligence in de novo drug design for COVID-19 pharmaceutical research. |
| first_indexed | 2024-03-09T19:41:37Z |
| format | Article |
| id | doaj.art-a8d30f8793cc419ab398e40d09b14367 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T19:41:37Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-a8d30f8793cc419ab398e40d09b143672023-11-24T01:35:56ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-03-01236326110.3390/ijms23063261Artificial Intelligence Technologies for COVID-19 De Novo Drug DesignGiuseppe Floresta0Chiara Zagni1Davide Gentile2Vincenzo Patamia3Antonio Rescifina4Dipartimento di Scienze del Farmaco e della Salute, Università di Catania, Viale A. Doria 6, 95125 Catania, ItalyDipartimento di Scienze del Farmaco e della Salute, Università di Catania, Viale A. Doria 6, 95125 Catania, ItalyDipartimento di Scienze del Farmaco e della Salute, Università di Catania, Viale A. Doria 6, 95125 Catania, ItalyDipartimento di Scienze del Farmaco e della Salute, Università di Catania, Viale A. Doria 6, 95125 Catania, ItalyDipartimento di Scienze del Farmaco e della Salute, Università di Catania, Viale A. Doria 6, 95125 Catania, ItalyThe recent covid crisis has provided important lessons for academia and industry regarding digital reorganization. Among the fascinating lessons from these times is the huge potential of data analytics and artificial intelligence. The crisis exponentially accelerated the adoption of analytics and artificial intelligence, and this momentum is predicted to continue into the 2020s and beyond. Drug development is a costly and time-consuming business, and only a minority of approved drugs generate returns exceeding the research and development costs. As a result, there is a huge drive to make drug discovery cheaper and faster. With modern algorithms and hardware, it is not too surprising that the new technologies of artificial intelligence and other computational simulation tools can help drug developers. In only two years of covid research, many novel molecules have been designed/identified using artificial intelligence methods with astonishing results in terms of time and effectiveness. This paper reviews the most significant research on artificial intelligence in de novo drug design for COVID-19 pharmaceutical research.https://www.mdpi.com/1422-0067/23/6/3261artificial intelligencemachine learningdrug designCOVID-19structure-based drug designligand-based drug design |
| spellingShingle | Giuseppe Floresta Chiara Zagni Davide Gentile Vincenzo Patamia Antonio Rescifina Artificial Intelligence Technologies for COVID-19 De Novo Drug Design International Journal of Molecular Sciences artificial intelligence machine learning drug design COVID-19 structure-based drug design ligand-based drug design |
| title | Artificial Intelligence Technologies for COVID-19 De Novo Drug Design |
| title_full | Artificial Intelligence Technologies for COVID-19 De Novo Drug Design |
| title_fullStr | Artificial Intelligence Technologies for COVID-19 De Novo Drug Design |
| title_full_unstemmed | Artificial Intelligence Technologies for COVID-19 De Novo Drug Design |
| title_short | Artificial Intelligence Technologies for COVID-19 De Novo Drug Design |
| title_sort | artificial intelligence technologies for covid 19 de novo drug design |
| topic | artificial intelligence machine learning drug design COVID-19 structure-based drug design ligand-based drug design |
| url | https://www.mdpi.com/1422-0067/23/6/3261 |
| work_keys_str_mv | AT giuseppefloresta artificialintelligencetechnologiesforcovid19denovodrugdesign AT chiarazagni artificialintelligencetechnologiesforcovid19denovodrugdesign AT davidegentile artificialintelligencetechnologiesforcovid19denovodrugdesign AT vincenzopatamia artificialintelligencetechnologiesforcovid19denovodrugdesign AT antoniorescifina artificialintelligencetechnologiesforcovid19denovodrugdesign |